Shannon Wakeley, MD
Endocrinology, Diabetes & Metabolism · Lincoln, NENPI 1942350905
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,951 of the $77,985 with a category attached, or 85.9%. 37 manufacturers reported payments, led by Amgen at 46.0% of the total. Reporting peaked in 2019 at $71,361 and has fallen 100.0% since, to $35 in 2025. Among endocrinology, diabetes & metabolism clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 382 payments — averaging $204.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$36K
- Lilly USA, LLC$7K
- Novo Nordisk$7K
- AstraZeneca$5K
- Boehringer Ingelheim$5K
- Sanofi-aventis U.S. LLC$5K
- plus $13K from 31 others
Across 62 payments — averaging $3656.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$221K
- Ascendis Pharma Endocrinology Inc$6K
What the payments were for
- Consulting fees$2,1133%
- Speaking & faculty fees$66,95186%
- Travel & lodging$2,9194%
- Food & beverage$5,6657%
- Education$2790%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 50 | $35,897 |
| Lilly USA, LLC | 63 | $7,232 |
| Novo Nordisk | 50 | $6,826 |
| AstraZeneca(2 entities) | 24 | $5,425 |
| Boehringer Ingelheim | 12 | $4,612 |
| Sanofi-aventis U.S. LLC | 22 | $4,538 |
| AbbVie | 9 | $3,844 |
| Medtronic(2 entities) | 13 | $3,173 |
| Dexcom, Inc. | 8 | $2,587 |
| Valeritas, Inc. | 9 | $1,796 |
| Ascensia Diabetes Care US Inc. | 23 | $321 |
| Abbott | 15 | $215 |
| Mannkind Corporation | 9 | $202 |
| Corcept Therapeutics | 8 | $184 |
| Tandem Diabetes Care, Inc. | 10 | $150 |
| Antares Pharma, Inc. | 7 | $129 |
| Zealand Pharma US, Inc. | 7 | $116 |
| Amneal Pharmaceuticals LLC | 5 | $84 |
| Insulet Corporation | 3 | $68 |
| Xeris Pharmaceuticals, Inc. | 3 | $65 |
| Recordati_rare_diseases_inc. | 3 | $57 |
| Amryt Pharma Holdings Ltd | 4 | $56 |
| Amarin Pharma, Inc. | 3 | $51 |
| BETA Bionics, Inc. | 3 | $49 |
| Ipsen Biopharmaceuticals, Inc | 3 | $46 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Nevro Corp. | 2 | $35 |
| Lifescan, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 1 | $28 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Eisai Inc. | 1 | $20 |
| Halozyme Inc | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $15 |
| Bayer | 1 | $13 |
| Radius Health, Inc. | 1 | $11 |
| IBSA Pharma Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$35,242
- Tresiba$6,096
- TRULICITY$6,025
- FARXIGA$5,112
- JARDIANCE$4,888
- SOLIQUA 100/33$4,253
- Synthroid$3,750
- DEXCOM CGM$2,490
- V-GO$1,650
How this compares
$77,985 in reported general payments places this provider in the 95th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IsturisaOsilodrostat Phosphate | 11 | $121,821 |
| OzempicSemaglutide | 74 | $82,733 |
| TrulicityDulaglutide | 41 | $48,605 |
| MounjaroTirzepatide | 44 | $46,953 |
| JardianceEmpagliflozin | 24 | $23,644 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $23,603 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $19,792 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $18,083 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $15,701 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $14,074 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $13,940 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $11,526 |
| SynthroidLevothyroxine Sodium | 85 | $9,126 |
| HumalogInsulin Lispro | 23 | $7,565 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $6,494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Recordati_rare_diseases_inc.Isturisa | $57 | $121,82111 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $7,232 | $103,123108 claims |
| Novo NordiskOzempic, Novolog | $6,826 | $86,48786 claims |
| Boehringer IngelheimJardiance | $4,612 | $23,64424 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $4,538 | $19,79223 claims |
| AbbVieSynthroid | $3,844 | $9,12685 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $84 | $1,020119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
Other endocrinology, diabetes & metabolism in Lincoln
- Madeline Jones RyanLincoln$4K
- Kara Meinke BaehrLincoln$1K
- Prathima JastiLincoln$1K
- Jalal NafachLincoln$110
- Marium IlahiOmaha$170K
- Cyrus DesouzaOmaha$86K
- Timothy WahlOmaha$41K
- Leslie EilandOmaha$17K
- Anupam KotwalOmaha$17K
- John GallagherOmaha$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.